Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer
Recruiting · NCT06160323 · Interventional (participants receive a specific treatment) · Lead sponsor: Chinese University of Hong Kong
View the official record on ClinicalTrials.gov →Interventions studied
EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis
What this trial is about
Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age \>= 18 years old
- Diagnosed to have inoperable pancreatic cancer
- Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \>= 3
- Karnofsky performance status \>= 60
- Planned for EUS examination and/or biopsy of the pancreatic tumor
Exclusion criteria
- Allergy to bupivacaine, or alcohol
- Potentially operable after neoadjuvant therapy
- Expected survival of less than 3 months
- Patient who is already on opioids for pain control
- Previous percutaneous or EUS-guided CGN/ CPN
- Recurrent pancreatic tumors after operation
- Uncorrectable coagulopathy
- Inability or unwillingness to provide informed consent
Where it is running
1 location listed.
- Prince of Wales Hospital - Hong Kong, Hong Kong, Hong Kong